Investigating how IL17 affects liver inflammation in alcoholic hepatitis
IL17 dependent angiocrine signaling drives inflammation in alcohol associated hepatitis
This study is looking at how a substance called IL17 affects inflammation in people with alcoholic hepatitis, a serious liver condition caused by drinking too much alcohol, and it aims to learn more about how certain liver cells attract immune cells that cause this inflammation, with the help of patients who may share samples or information.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10892750 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of IL17, a cytokine, in driving inflammation in alcoholic hepatitis, a condition characterized by severe liver injury due to excessive alcohol consumption. The study will explore how liver sinusoidal endothelial cells (LSECs) produce chemokines that attract immune cells, contributing to inflammation. By using advanced techniques like RNA sequencing and cell biology methods, the researchers aim to uncover the mechanisms by which IL17 influences immune responses in the liver. Patients may be involved in providing samples or data to help elucidate these processes.
Who could benefit from this research
Good fit: Ideal candidates for participation would include individuals diagnosed with alcoholic hepatitis who are experiencing significant liver inflammation.
Not a fit: Patients with liver conditions unrelated to alcohol consumption or those without significant liver inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing alcoholic hepatitis and reducing liver inflammation.
How similar studies have performed: Previous research has shown promising results in understanding cytokine roles in liver diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Liu, Mengfei — Yale University
- Study coordinator: Liu, Mengfei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.